Chemours (CC)
(Delayed Data from NYSE)
$24.32 USD
+0.43 (1.80%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $24.33 +0.01 (0.04%) 7:58 PM ET
5-Strong Sell of 5 5
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$24.32 USD
+0.43 (1.80%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $24.33 +0.01 (0.04%) 7:58 PM ET
5-Strong Sell of 5 5
C Value D Growth D Momentum D VGM
Zacks News
3 Reasons Why Chemours (CC) Is a Great Growth Stock
by Zacks Equity Research
Chemours (CC) possesses solid growth attributes, which could help it handily outperform the market.
Are You Looking for a Top Momentum Pick? Why Chemours (CC) is a Great Choice
by Zacks Equity Research
Does Chemours (CC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Chemours (CC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
6 Stocks Trading Near 52-Week Highs That Can Appreciate Further
by Anirudha Bhagat
Investors target stocks that have been on a bullish run, lately. Stocks seeing price strength have higher chances of carrying the momentum ahead.
Chemours (CC) Stock Rallies 79% in 6 Months: What's Driving It?
by Zacks Equity Research
Chemours (CC) gains on a recovery in demand from the coronavirus-induced slowdown, strong execution and its cost-reduction measures.
Global Chemical Output Leaps for Sixth Straight Month: 5 Picks
by Anindya Barman
The chemical industry has recovered from the pandemic-led slump and looks set for an upturn this year on a rebound in end-market demand. CBT, HUN, CC, PPG and CE to gain from the industry's recovery.
5 Chemical Stocks Poised to Maintain Winning Streak in 2021
by Anindya Barman
A rebound in China, demand upturn across major markets and recovering manufacturing activities augur well for the chemical industry heading into 2021.
What Makes Chemours (CC) Stock a Solid Choice Right Now
by Zacks Equity Research
Chemours (CC) benefits from demand recovery, cost-management initiatives and strong execution.
4 Diversified Chemical Stocks Set to Ride the Industry's Upturn
by Anindya Barman
An uptick in demand in key end-markets from pandemic-led shocks should enable the Zacks Chemicals Diversified industry to thrive. PPG, CC, CBT and KOP are set to gain from improving industry fundamentals and strategic actions.
Is Chemours Company (CC) a Good Value Investor Stock Now?
by Zacks Equity Research
Let's see if The Chemours Company (CC) stock is a good choice for value-oriented investors right now from multiple angles.
New Strong Buy Stocks for December 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
US Chemical Industry Set for Strong Rebound in 2021: 5 Picks
by Anindya Barman
The U.S. chemical industry is poised for an upturn next year on a rebound across major end-markets and a recovery in chemical exports.
Chemours (CC) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Chemours (CC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Chemours (CC) Up 30% in 3 Months: What's Driving the Rally?
by Zacks Equity Research
Chemours (CC) gains on a recovery in demand from the coronavirus-induced slowdown and its cost-reduction measures.
Is Chemours (CC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemours (CC) Up 19.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Chemical Output Leaps as Recovery Continues to Take Hold
by Anindya Barman
A rebound in demand across major end markets has put the wind back in the sails of the chemical industry.
Here's Why You Should Add Chemours (CC) to Your Portfolio
by Zacks Equity Research
Chemours (CC) benefits from demand recovery across its markets and its cost-cutting actions.
Chemours (CC) Closes Offering Of $800M Senior Notes Due 2028
by Zacks Equity Research
Chemours (CC) to use the net proceeds along with cash on hand to finance the purchase price as well as unpaid and accrued interest of senior notes due 2023.
Chemours (CC) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Chemours (CC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Univar's (UNVR) Unit to Distribute Viton Fluoroelastomers
by Zacks Equity Research
Univar's (UNVR) ChemPoint's technical expertise across multiple industry segments helps reach new markets and applications to support growth of Viton fluoroelastomers.
Why Chemours (CC) is Such a Great Value Stock Pick Right Now
by Zacks Equity Research
Chemours (CC) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
Is Chemours (CC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemours (CC) Prices Offering Of $800M Senior Notes Due 2028
by Zacks Equity Research
Chemours (CC) to employ the net proceeds along with cash on hand to fund the purchase price as well as unpaid and accrued interest of senior notes due 2023.
All You Need to Know About Chemours (CC) Rating Upgrade to Strong Buy
by Zacks Equity Research
Chemours (CC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).